- Home
- MCRB vs HEQ Comparison
MCRB vs HEQ Comparison
Compare MCRB & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- HEQ
- Stock Information
- Founded
- MCRB 2010
- HEQ 2011
- Country
- MCRB United States
- HEQ United States
- Employees
- MCRB N/A
- HEQ N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- HEQ Investment Managers
- Sector
- MCRB Health Care
- HEQ Finance
- Exchange
- MCRB Nasdaq
- HEQ Nasdaq
- Market Cap
- MCRB 144.6M
- HEQ 129.0M
- IPO Year
- MCRB 2015
- HEQ N/A
- Fundamental
- Price
- MCRB $20.47
- HEQ $10.62
- Analyst Decision
- MCRB Hold
- HEQ
- Analyst Count
- MCRB 4
- HEQ 0
- Target Price
- MCRB $14.33
- HEQ N/A
- AVG Volume (30 Days)
- MCRB 227.9K
- HEQ 43.1K
- Earning Date
- MCRB 11-12-2025
- HEQ 01-01-0001
- Dividend Yield
- MCRB N/A
- HEQ 9.78%
- EPS Growth
- MCRB N/A
- HEQ N/A
- EPS
- MCRB 10.22
- HEQ N/A
- Revenue
- MCRB N/A
- HEQ N/A
- Revenue This Year
- MCRB N/A
- HEQ N/A
- Revenue Next Year
- MCRB N/A
- HEQ N/A
- P/E Ratio
- MCRB $2.05
- HEQ N/A
- Revenue Growth
- MCRB N/A
- HEQ N/A
- 52 Week Low
- MCRB $6.53
- HEQ $9.08
- 52 Week High
- MCRB $24.67
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- MCRB 60.09
- HEQ 52.28
- Support Level
- MCRB $19.14
- HEQ $10.51
- Resistance Level
- MCRB $21.97
- HEQ $10.74
- Average True Range (ATR)
- MCRB 1.52
- HEQ 0.13
- MACD
- MCRB 0.22
- HEQ 0.00
- Stochastic Oscillator
- MCRB 80.36
- HEQ 58.70
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.